A poor drug-resistant tuberculosis programme is worse than no programme: Time for a change

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 6, 2013, Pages 714-718

  Chiang, Chen Yuan ^a,b   Van Deun, A ^a,c   Enarson, D A ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

BACTERIAL TRANSMISSION; BACTERIUM CULTURE; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH PROGRAM; HUMAN; MICROBIOLOGICAL EXAMINATION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK REDUCTION; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; EARLY DIAGNOSIS; HUMANS; NATIONAL HEALTH PROGRAMS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84878269364     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0989     Document Type: Review

References (27)

1. Enarson D A. Principles of IUATLD collaborative tuberculosis programmes. Bull Int Union Tuberc Lung Dis 1991; 66(4): 195-200.
2. Kochi A. Ten-year collaboration of IUATLD with national tuberculosis programmes in developing countries. WHO standpoint. Bull Int Union Tuberc Lung Dis 1991; 66 (Suppl): 43-44.
3. World Health Organization. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. WHO/CDS/CPC/TB/99.270. Geneva, Switzerland: WHO, 1999.
4. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
5. World Health Organization. WHO report 2008. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
6. World Health Organization. WHO report 2009. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TM/2009.411. Geneva, Switzerland: WHO, 2009.
7. World Health Organization. WHO report 2010. Global tuberculosis control. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
8. World Health Organization. WHO report 2011. Global tuberculosis control. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
9. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
10. Blower S, Supervie V. Predicting the future of XDR tuberculosis (Reflection and reaction). Lancet Infect Dis 2007; 7: 443. (Pubitemid 46962341)
11. World Health Organization. WHO Expert Committee on Tuberculosis. Eighth report. Technical Report Series no. 290. Geneva, Switzerland: WHO, 1964.
12. Grzybowski S, Enarson D. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis 1978; 53 (2): 70-75. (Pubitemid 9240283)
13. National Tuberculosis Institute, Bangalore, India. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 1974; 51: 473-489.
14. Springett V H. Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle 1971; 52: 73-87.
15. Enarson D A. Tuberculosis control in low income countries. In: Reichman L B, Hershfield E S, eds. Tuberculosis: a comprehensive international approach. Lung Biology Series, 2nd ed. New York, NY, USA: Marcel Dekker, 2000: pp 55-73.
16. Enarson D A. Foreword. In: Davies P D O, ed. Clinical tuberculosis. 3rd ed. London, UK: Arnold, 2003: xii-xv.
17. Falzon D, Jaramillo E, Schünemann H J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
19. Ahuja S D, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J N, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PloS Med 2012; 9(8): e1001300.
20. Van Deun A, Kya Jai Maug A, Halim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
21. Chiang C-Y, Schaaf H S. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 672-682.
22. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
23. Chan P-C, Huang S-H, Yu M-C, et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients - a retrospective cohort study. PLoS ONE 2013; 8(2): e57719.
24. Van Deun A, Maug A K J. 9-month standardised MDR-TB regimen in Bangladesh: an update. Invited oral presentation at 43th Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 2012. Int J Tuberc Lung Dis 2012; 16 (Supp 1): S42. [Abstract]
25. Kuaban C, Noeske J, Abena J L, Aït-Khaled N, Rieder H, Trébucq A. 12-month standardised MDR-TB regimen: experience in Cameroon. Invited oral presentation at 43th Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 2012. Int J Tuberc Lung Dis 2012; 16 (Supp 1): S43. [Abstract]
26. Weyer K, Mirzayev F, Migliori G B, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert® MTB/RIF. Eur Respir J 2012; 22 Nov. [epub ahead of print]
27. Chiang C-Y, Van Deun A, Trébucq A, Heldal E, Caminero J A, Aït-Khaled N. Treatment of multidrug-resistant tuberculosis: definition of the outcome 'failure'. Int J Tuberc Lung Dis 2011; 15: 4-5.